top of page
  • Completed
    • Dec 13, 2014

NCT02045017: Phase 2: Efficacy & Safety of Pom and Dex in RRMM Patients With Renal Insufficiency

Updated: Sep 27, 2022


NCT02045017: Phase 2: Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

pom-dex-myeloma

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency


The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple myeloma, with moderate or severe renal impairment.


Sponsor:

Celgene


Multiple Locations

International Study

Europe

 

ClinicalTrials.gov Identifier: NCT02045017

Official Title: A Phase 2 Multicenter, Open-label Study to Determine the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Moderate or Severe Renal Impairment Including Subjects Undergoing H